LENSAR Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

LENSAR wird ein Gewinn- und Umsatzwachstum von 33.9% bzw. 22% pro Jahr prognostiziert, während der Gewinn pro Aktie um 36.4% pro Jahr wachsen soll.

Wichtige Informationen

33.9%

Wachstumsrate der Gewinne

36.4%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.7%
Wachstumsrate der Einnahmen	22.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing LENSAR, Inc.'s (NASDAQ:LNSR) CEO Pay Packet

May 01

LENSAR, Inc.'s (NASDAQ:LNSR) Shares Leap 33% Yet They're Still Not Telling The Full Story

Feb 22

Here's Why We're Not Too Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation

Nov 01

LENSAR GAAP EPS of -$0.67, revenue of $8M

Aug 08

LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans

Mar 23

We Think LENSAR (NASDAQ:LNSR) Can Afford To Drive Business Growth

Jul 28

LENSAR EPS misses by $0.23, beats on revenue

May 05

What You Need To Know About LENSAR, Inc.'s (NASDAQ:LNSR) Investor Composition

Feb 25

We're Keeping An Eye On LENSAR's (NASDAQ:LNSR) Cash Burn Rate

Jan 03

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:LNSR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	84	-2	N/A	N/A	1
12/31/2025	62	-10	N/A	N/A	2
12/31/2024	51	-12	N/A	N/A	2
3/31/2024	45	-12	-9	-8	N/A
12/31/2023	42	-14	-10	-10	N/A
9/30/2023	40	-13	-14	-14	N/A
6/30/2023	38	-18	-19	-18	N/A
3/31/2023	34	-18	-19	-19	N/A
12/31/2022	35	-20	-15	-15	N/A
9/30/2022	36	-21	-11	-11	N/A
6/30/2022	37	-23	-9	-8	N/A
3/31/2022	37	-21	-7	-7	N/A
12/31/2021	34	-20	-9	-9	N/A
9/30/2021	32	-23	-11	-10	N/A
6/30/2021	30	-21	-8	-8	N/A
3/31/2021	28	-21	-12	-12	N/A
12/31/2020	26	-20	-14	-14	N/A
9/30/2020	27	-15	-19	-19	N/A
6/30/2020	27	-16	-22	-21	N/A
3/31/2020	29	-15	-19	-17	N/A
12/31/2019	31	-15	-15	-13	N/A
12/31/2018	24	-14	-5	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: LNSR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: LNSR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: LNSR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: LNSRDie Einnahmen des Unternehmens (22% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: LNSRDie Einnahmen des Unternehmens (22% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von LNSR in 3 Jahren voraussichtlich hoch sein wird

LENSAR Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 42%

Consensus EPS estimates upgraded to US$1.62 loss, revenue downgraded

Consensus EPS estimates fall by 35%, revenue upgraded

Price target decreased by 20% to US$12.00

Consensus forecasts updated

Consensus forecasts updated

Recent updates

First quarter 2024 earnings: EPS exceeds analyst expectations

LENSAR, Inc. to Report Q1, 2024 Results on May 09, 2024

Here's Why Shareholders May Want To Be Cautious With Increasing LENSAR, Inc.'s (NASDAQ:LNSR) CEO Pay Packet

LENSAR, Inc., Annual General Meeting, May 07, 2024

Consensus EPS estimates fall by 42%

Full year 2023 earnings: EPS exceeds analyst expectations

Insufficient new directors

LENSAR, Inc. to Report Q4, 2023 Results on Mar 04, 2024

LENSAR, Inc.'s (NASDAQ:LNSR) Shares Leap 33% Yet They're Still Not Telling The Full Story

Here's Why We're Watching LENSAR's (NASDAQ:LNSR) Cash Burn Situation

Not Many Are Piling Into LENSAR, Inc. (NASDAQ:LNSR) Just Yet

Consensus EPS estimates upgraded to US$1.62 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

LENSAR, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Here's Why We're A Bit Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation

New minor risk - Share price stability

LENSAR, Inc. Announces Retirement of John P. McLaughlin from the Board, Effective October 31, 2023

Investors Continue Waiting On Sidelines For LENSAR, Inc. (NASDAQ:LNSR)

Consensus EPS estimates fall by 35%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

LENSAR, Inc. to Report Q2, 2023 Results on Aug 09, 2023

LENSAR, Inc., Annual General Meeting, Aug 01, 2023

Insider recently bought US$85k worth of stock

LENSAR, Inc. announced that it has received $20 million in funding from NR-GRI Partners, LP

First quarter 2023 earnings released: US$0.40 loss per share (vs US$0.67 loss in 1Q 2022)

LENSAR, Inc. to Report Q1, 2023 Results on May 15, 2023

This Broker Just Slashed Their LENSAR, Inc. (NASDAQ:LNSR) Earnings Forecasts

Will LENSAR (NASDAQ:LNSR) Spend Its Cash Wisely?

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased by 20% to US$12.00

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

LENSAR, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Here's Why We're Not Too Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation

LENSAR, Inc. Announces First Patients Treated with LENSAR's(R) ALLY(TM) Adaptive Cataract Treatment System

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

LENSAR GAAP EPS of -$0.67, revenue of $8M

LENSAR, Inc. to Report Q2, 2022 Results on Aug 08, 2022

LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell Microcap Value Index

LENSAR, Inc. Receives U.S. FDA Clearance of Ally(Tm) Adaptive Cataract Treatment System

Consensus EPS estimates fall by 31%

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

LENSAR, Inc. to Report Q1, 2022 Results on May 09, 2022

Price target decreased to US$13.50

Consensus forecasts updated

LENSAR, Inc., Annual General Meeting, May 25, 2022

LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

LENSAR, Inc. Announces U.S. Food and Drug Administration Acceptance of 510(k) Submission for ALLY

LENSAR, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Third quarter 2021 earnings released: US$0.65 loss per share (vs US$0.64 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.47 loss per share (vs US$4.20 loss in 2Q 2020)

We Think LENSAR (NASDAQ:LNSR) Can Afford To Drive Business Growth

LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell 2000 Defensive Index

First quarter 2021 earnings released: US$0.56 loss per share (vs US$3.82 loss in 1Q 2020)

LENSAR EPS misses by $0.23, beats on revenue

Full year 2020 earnings released: US$4.28 loss per share (vs US$1.52 loss in FY 2019)

Revenue beats expectations, earnings disappoint

LENSAR, Inc. to Report Q4, 2020 Results on Mar 10, 2021

What You Need To Know About LENSAR, Inc.'s (NASDAQ:LNSR) Investor Composition

LENSAR, Inc Announces Board Appointment

New 90-day low: US$6.64

We're Keeping An Eye On LENSAR's (NASDAQ:LNSR) Cash Burn Rate

LENSAR, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum